CRDL - CONSENSUS CO - Cardiol Therapeutics

The price action history of Cardiol Therapeutics (CRDL) demonstrates the current indicator 7.92. Cardiol Therapeutics develops treatments for cardiac inflammation, with patent protection ensuring a stable inflow of capital. The business is currently focusing on developing safe steroid substitutes for the therapy of rare pericardial pathologies. Development is centered on the implementation of THC-free cannabidiol components to combat myocardial fibrosis.

This indicator represents the average target price of the asset, derived from estimates by leading investment houses to determine fair market value. Comparing the market price with the current consensus valuation forecast allows for the timely rebalancing of a Cardiol Therapeutics (CRDL) portfolio, accounting for the risks of depleting the company's cash reserves amid costly clinical trials in the absence of operating revenues.